Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
January 04 2023 - 8:01AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of January 2023
Commission File Number: 001-40617
Regencell Bioscience Holdings Limited
9/F Chinachem Leighton Plaza
29 Leighton Road
Causeway Bay, Hong Kong
(Address of principal executive office)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F ☒
Form 40-F ☐
Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Lock-up of Directors and Employees
All directors and employees who were previously granted stock options
have agreed to a further lock-up undertaking for an additional six months, until July 20, 2023, the second anniversary of the Company’s
initial public offering. Their shares will remain locked up until such date. A form of the lock-up undertaking is attached hereto as Exhibit
99.1.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: January 4, 2023
| |
Regencell Bioscience Holdings Limited |
| |
|
|
| |
By: |
/s/ Yat-Gai Au |
| |
Name: |
Yat-Gai Au |
| |
Title: |
Chief Executive Officer and
Chairman of the Board of Directors |
[Signature Page to Form 6-K]
EXHIBIT INDEX
3
Regencell Bioscience (NASDAQ:RGC)
Historical Stock Chart
From Dec 2024 to Jan 2025
Regencell Bioscience (NASDAQ:RGC)
Historical Stock Chart
From Jan 2024 to Jan 2025
